Northwestern Mutual Wealth Management Co. Boosts Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Northwestern Mutual Wealth Management Co. raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 25.9% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,101 shares of the biopharmaceutical company’s stock after acquiring an additional 1,048 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Regeneron Pharmaceuticals were worth $3,180,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Greenwood Capital Associates LLC grew its holdings in Regeneron Pharmaceuticals by 23.2% during the 2nd quarter. Greenwood Capital Associates LLC now owns 13,873 shares of the biopharmaceutical company’s stock valued at $8,650,000 after purchasing an additional 2,612 shares during the last quarter. New Mexico Educational Retirement Board raised its position in Regeneron Pharmaceuticals by 4.2% in the 2nd quarter. New Mexico Educational Retirement Board now owns 5,000 shares of the biopharmaceutical company’s stock worth $3,118,000 after purchasing an additional 200 shares during the period. Mufg Securities Americas Inc. lifted its stake in Regeneron Pharmaceuticals by 7.9% in the second quarter. Mufg Securities Americas Inc. now owns 3,010 shares of the biopharmaceutical company’s stock worth $1,877,000 after purchasing an additional 221 shares during the last quarter. Van ECK Associates Corp boosted its position in shares of Regeneron Pharmaceuticals by 4.4% during the second quarter. Van ECK Associates Corp now owns 65,332 shares of the biopharmaceutical company’s stock valued at $40,737,000 after buying an additional 2,748 shares during the period. Finally, Nissay Asset Management Corp Japan boosted its position in shares of Regeneron Pharmaceuticals by 6.1% during the second quarter. Nissay Asset Management Corp Japan now owns 30,636 shares of the biopharmaceutical company’s stock valued at $19,103,000 after buying an additional 1,767 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of analyst reports. Truist Financial upped their target price on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Piper Sandler dropped their price objective on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a report on Thursday, July 9th. Morgan Stanley upped their price objective on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the company an “equal weight” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. reduced their target price on Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating on the stock in a research note on Monday, May 18th. Finally, HSBC decreased their target price on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a research report on Monday, July 6th. Fourteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $800.36.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,215 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the transaction, the executive vice president directly owned 13,134 shares in the company, valued at $11,163,900. This represents a 8.47% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director directly owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 31.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 4,146 shares of company stock worth $3,432,488. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 1.0%

Shares of NASDAQ REGN opened at $843.47 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The firm has a market capitalization of $86.84 billion, a price-to-earnings ratio of 20.85, a PEG ratio of 1.67 and a beta of 0.20. The stock has a 50 day moving average price of $734.39 and a 200 day moving average price of $719.34. Regeneron Pharmaceuticals, Inc. has a 52-week low of $541.00 and a 52-week high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.Regeneron Pharmaceuticals’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $12.81 earnings per share. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th were paid a dividend of $0.94 per share. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.29%.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported that a Phase 1/2 study combining cemiplimab with SNS-101 has reached completion. The update provides a development milestone, although no efficacy or regulatory data were disclosed, limiting its immediate impact. Regeneron’s Cemiplimab Combo Trial With SNS-101 Reaches Completion
• Neutral Sentiment: Industry research projects substantial growth in the global complement-inhibitor market through 2035 and lists Regeneron among the leading companies. The report supports the company’s long-term opportunity but does not provide a new company-specific catalyst. 2026 Complement Inhibitors Market Analysis Report
• Negative Sentiment: Multiple law firms announced or promoted securities class actions involving investors who purchased REGN shares between August 1, 2025, and May 15, 2026. The lawsuits allege that Regeneron and certain executives misrepresented risks surrounding the Phase 3 Fianlimab-Libtayo melanoma trial, including a protocol change and eventual failure to meet its primary endpoint. Investors have until September 14, 2026, to seek lead-plaintiff status. The legal claims may increase reputational, litigation, and potential financial risks, although the allegations have not been proven. Hagens Berman Regeneron Securities Fraud Class Action Alert Robbins Geller Regeneron Investor Alert
• Negative Sentiment: Director Kathryn Guarini and EVP Marion McCourt reported sales totaling roughly $2.34 million. All transactions were executed under pre-arranged Rule 10b5-1 plans, reducing their significance as discretionary bearish signals, but the sales can still weigh on sentiment near the stock’s recent highs. SEC insider transaction filing

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.